Lv1
50 积分 2024-11-28 加入
Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction–Associated Steatohepatitis
20天前
已完结
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
20天前
已完结
Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists
3个月前
已完结
皖公网安备34019202002308
